QNRX logo

QNRXQuoin Pharmaceuticals Ltd - ADR

$4.49
$0.20
(4.66%)
Today
Closed $4.49
$0.10
(2.23%)
After Hours
Updated: 07:43 PM EDT
Mkt Cap$8.81M
Vol20,203.00
News
all
press releases
Quoin Pharmaceuticals Garners Buzz After FDA’s Comments On Netherton Syndrome Lead Drug
The U.S. Food and Drug Administration indicated that a single Phase 3 trial of QRX003 could be enough to support approval in the U.S.
Stocktwits
News Placeholder
More News
News Placeholder
Quoin Pharmaceuticals Gains FDA Alignment, Eyes Streamlined Path to First Netherton Syndrome Treatment
Quoin Pharmaceuticals (NASDAQ:QNRX) reported a key regulatory milestone following a constructive Type C meeting with the U.S. Food and Drug Administration (FDA), potentially accelerating the development path for its lead candidate, QRX003, in the treatment of Netherton Syndrome, a rare and underserved genetic skin disorder.
24-7 Market News
News Placeholder
QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally?
A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.
Stocktwits
News Placeholder
QNRX Stock Soars 300% After $104.5M Financing Through Private Placement
Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.
Stocktwits
News Placeholder
Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data
The stock closed up 20% on Wednesday, driven by promising patient outcomes and no reported adverse events for its Pediatric Peeling Skin Syndrome (PSS) drug, with further treatment and evaluations planned.
Stocktwits
<
...
1
>

Advertisement|Remove ads.